NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Avalyn Pharma AVLN

Avalyn Pharma listed on Nasdaq on 30 Apr 2026 and is not in the S&P 500. It is worth $1.3 billion. Its price history starts on 1 May 2026. 8 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 4 other officers are on file. At 30 Jun 2026, Fidelity (FMR) was its largest institutional holder, with 13.2% of the company.

CEO
Lyn Baranowski
Listed
30 Apr 2026 on Nasdaq, IPO filings and terms
Headquarters
Boston, MA
Market cap
$1.3B
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Avalyn Pharma's market cap since May 2026

Weekly, up to 13 Nov 2026

Jun 2026JulAugSepOctNov$1.4B

Board and leadership

Board and officers

Roles filed up to 30 Sep 2026

NameTitle
Directors (8)
Lyn BaranowskiChief Executive OfficerChief Executive Officer
Jill CarrollDirectorDirector
Jon CongletonDirectorDirector
David Matthew FriedmanDirectorDirector
Kate HavilandDirectorDirector
Erin LavelleDirectorDirector
Robert J. MeyerDirectorDirector
Heather D. TurnerDirectorDirector
Officers (4)
Douglas R. CarlsonChief Financial OfficerLast filed 1 May 2026Chief Financial Officer
Adam H. GoldenGeneral CounselLast filed 4 May 2026General Counsel
Howard LazarusChief Medical OfficerLast filed 1 May 2026Chief Medical Officer
Melissa RhodesChief Operating OfficerLast filed 1 May 2026Chief Operating Officer

Owners and trading

Largest institutional holders

Each fund group's share of Avalyn Pharma. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 42.9% of Avalyn Pharma.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $2.6 million of stock in 5 sales and bought $5.0 million in 1 purchase in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
18 Nov 2026SaleLyn BaranowskiChief Executive OfficerChief Executive OfficerSale7,200$201K
17 Nov 2026SaleLyn BaranowskiChief Executive OfficerChief Executive OfficerSale45,300$1.3M
17 Nov 2026SaleDouglas R. CarlsonChief Financial OfficerChief Financial OfficerSale14,875$415K
17 Nov 2026SaleMelissa RhodesChief Operating OfficerChief Operating OfficerSale13,300$371K
17 Nov 2026SaleHoward LazarusChief Medical OfficerChief Medical OfficerSale13,300$371K
1 May 2026BuyJill CarrollDirectorDirectorBuy277,778$5.0M

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

0 departures and 1 appointment of directors and officers and 1 large insider sale in the last two years.

Left the company or board 0Appointed 1WARN layoff notices 0Large insider sales 1Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Avalyn Pharma's insider sales.

Events, newest first

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.